New research reveals that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who halt traditional diet and exercise programs.
Research printed in a major health publication shows that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals buying such medications must be cognizant of the risk of fast weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to starting weight within about one and a half years.
Comparing Approaches
The analysis, which examined 37 of trials involving thousands of patients, compared the results of these new drugs with older methods.
Researchers note that individuals who lose weight through diet and exercise generally experience a more gradual weight regain—around 100 grams monthly—post-intervention.
Understanding the Fast Regain
Nutrition scientists propose the mode of action of the drugs is key to understanding the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is no longer kept in check, making overeating far more likely."
An Ongoing Issue?
The NHS recommend the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians say that, due to the likelihood of weight regain, the treatment is often life-long.
This view is echoed by drug manufacturers, who state that the results "emphasize the chronic nature of excess weight," comparing it to managing diseases like hypertension.
Patient Experiences
Users who have discontinued the medication explain a intense return of hunger.
"I experienced a switch activating and you're instantly starving," described one woman.
This challenge is exacerbated if users have not developed permanent lifestyle or habit changes during treatment.
Growing Use
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Use is more common among females compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while these medications are potent agents for weight loss, they are not a magic cure and lasting health benefits likely depends on ongoing behavioural changes.
